false
0001493137
0001493137
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): November 16, 2026
LIFELOC TECHNOLOGIES,
INC.
(Exact name of registrant
as specified in its charter)
| Colorado |
|
000-54319 |
|
84-1053680 |
| (State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
| 12441 West 49th Ave., Unit 4 |
|
|
| Wheat Ridge, CO |
|
80033 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
(303) 431-9500
(Registrant’s
telephone number, including area code)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On November 16, 2026,
Lifeloc Technologies, Inc. (the “Company”) issued a press release announcing its operating results for the period ended
September 30, 2026. This press release was made available on the Company’s website as of November 16, 2026. A copy of the press
release is furnished herewith as Exhibit 99.1.
The information in
this Form 8-K, including the exhibit attached hereto, is being “furnished” and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended,
unless expressly set forth by specific reference in such filing that such information is incorporated by reference therein.
| Item 9.01 |
Financial Statements and Exhibits. |
| |
|
(d) Exhibits.
| Exhibit No. |
Description |
| |
|
| 99.1 |
Press Release, dated November 16, 2026, issued by the Company |
| |
|
| 104 |
Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| |
|
SIGNATURES
Pursuant to the
requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| Date: November 16, 2026 |
LIFELOC TECHNOLOGIES, INC. |
| |
|
|
| |
By: |
/s/ Vern D. Kornelsen |
| |
|
Chief Financial Officer and Secretary |
Exhibit 99.1
Lifeloc Reports
Third Quarter 2026 Results
WHEAT RIDGE, Colo., November
16, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and
drug testing devices, has announced financial results for the quarter ended September 30, 2026.
Third Quarter
Financial Highlights
Lifeloc posted quarterly
net revenue of $2.522 million in the third quarter of 2026, resulting in a quarterly net loss of $(85) thousand, or $(0.03) per
diluted share. These results compare to net revenue of $2.257 million and quarterly net loss of $(263) thousand, or $(0.10) per
diluted share in the third quarter of 2025. Revenue for the quarter grew 12% versus the third quarter last year. For the first nine months
of 2026, net revenue was $7.261 million and net loss was $(372) thousand, or $(0.14) per diluted share, compared with net revenue of $6.754
million and net loss of $(950) thousand, or $(0.35) per diluted share, for the same period in 2025. Total gross margin in the third quarter
rose to 43% versus 40% for the same quarter last year. For the first nine months of 2026, gross margin was 44% versus 41% for the same
period last year, with price increases and a favorable product mix contributing to the higher margins. The research and development investment
for the quarter remained high at $506 thousand, primarily for SpinDetect™ analyzer development, resulting in the current period
loss.
Alcohol Detection
Products
We believe our core
alcohol detection product lineup is strong. The L-series LX9 and LT7 units have features and performance that drive market penetration
by addressing previously unmet market needs such as smartphone pairing, wider temperature use ranges and fast customization that incorporates
local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC
sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as the latest AS
3547:2019 standards for Breath Alcohol Detectors from SAI Global (formerly Standards Australia International). Our FC-series devices remain
popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated
calibration available for portable breath alcohol testers, builds valuable protection around our brand and has contributed to market share
gains across the board, especially for our workplace Phoenix® 6.0 BT and EV 30 devices.
SpinDetect™
Analyzer Platform
We believe our most
significant long-term opportunity lies at the intersection of the global need for rapid, quantitative drug detection and our proven expertise
in portable testing instrumentation. Our SpinDetect™ Centrifugal Drug Analyzer — sometimes referred to as "Lab on a Disk"
— is designed to address this need, enabling rapid, on-site, quantitative drug testing for use at roadside, in emergency rooms,
forensic labs, and workplace testing sites. We have demonstrated the platform's ability to effectively detect delta-9-THC, cocaine, fentanyl,
amphetamine/methamphetamine, morphine, MDMA, and benzodiazepines from oral fluid. We have validated our test results against liquid chromatography-mass
spectrometry (LC-MS) — the definitive laboratory standard — using real-world human saliva samples, confirming a limit of detection
of approximately 10 ng/ml.
We have completed
the design of the SpinDetect™ microfluidic disk, with all analytical chemistry now occurring on the disk after sample introduction.
We will be initiating beta testing of the oral-fluid analyzer focused on delta-9-THC detection using a prototype reader, with final component
optimization underway, under a signed beta-testing agreement. The full commercial product is expected to measure delta-9-THC, followed
by a multi-drug panel release. We previously anticipated a limited commercial launch of SpinDetect in Q1 of 2027; we now expect the limited
commercial launch to occur in Q4 of 2027. In recent periods we devoted a substantial portion of our engineering and development resources
to SpinDetect and, as a result, deferred upgrades and enhancements to our core breath alcohol testing products. We are redirecting a portion
of those resources to our core products in the near term and will be conducting beta testing and the validation of SpinDetect with our
current staff rather than with additional personnel. The upgrades to our core products will allow us to enter additional markets and generate
incremental revenue, which we expect will help fund the work required to complete and bring SpinDetect to market.
Following the limited
commercial launch, we plan to expand into additional drug panels and sample types, including blood and breath — the latter integrated
with our LX9 breathalyzer. The SpinDetect™ reader is designed to accept multiple disk formats, which may also enable future applications
beyond drug testing, such as detection of food-safety markers and environmental contaminants; these applications would require additional
research, regulatory clearances, and potential expansion of our existing license rights. Our revised timeline and continued progress toward
commercialization depend on our ability to generate the anticipated incremental revenue from our core products and on timely access to
capital to support fabrication, validation, regulatory preparation, and market introduction. There can be no assurance that the launch
will occur when currently expected.
“We are raising
the priority of our alcohol testing research and development projects that can have a quick, positive impact on cash flow. While we had
deferred some core business opportunities, transformational AI tools have reduced the cost and timeline for hardware and firmware upgrades,
raising the return on investment for these projects,” commented Dr. Wayne Willkomm, President and CEO. “Using advances in
our core products to fund the big growth opportunity of the SpinDetect™ Centrifugal Drug Analyzer is consistent with our desire
to fund from operations as best as we can.”
About Lifeloc Technologies
Lifeloc Technologies, Inc. (OTCID: LCTC)
is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement,
Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company
with our SEC filings available on our website, www.lifeloc.com/investor.
Forward Looking Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties
that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements
expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing
products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and
growth, market liquidity for our shares, and return on investments in products and market, are based on information available to us on
the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to
review the section titled “Risk Factors” in our SEC filings.
Phoenix® and
Easycal® are registered trademarks of Lifeloc Technologies, Inc.
SpinDetect™
is a trademark of Lifeloc Technologies, Inc.
Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500
LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets (Unaudited)
| |
|
|
|
|
|
|
|
|
| ASSETS |
|
|
|
|
|
|
| CURRENT ASSETS: |
|
September 30, 2026 |
|
|
December 31, 2025 |
|
| Cash and cash equivalents |
|
$ |
930,539 |
|
|
$ |
746,001 |
|
| Accounts receivable, net |
|
|
785,442 |
|
|
|
772,380 |
|
| Inventories, net |
|
|
2,678,034 |
|
|
|
2,633,614 |
|
| Federal and state income taxes receivable |
|
|
55,381 |
|
|
|
55,981 |
|
| Prepaid expenses and other |
|
|
96,747 |
|
|
|
60,825 |
|
| Total current assets |
|
|
4,546,143 |
|
|
|
4,268,801 |
|
| |
|
|
|
|
|
|
|
|
| PROPERTY, PLANT AND EQUIPMENT: |
|
|
|
|
|
|
|
|
| Land |
|
|
317,932 |
|
|
|
317,932 |
|
| Building |
|
|
1,928,795 |
|
|
|
1,928,795 |
|
| Real-time Alcohol Detection And Recognition equipment and software |
|
|
569,448 |
|
|
|
569,448 |
|
| Production equipment, software and space modifications |
|
|
1,366,539 |
|
|
|
1,366,539 |
|
| Office equipment, software and space modifications |
|
|
197,686 |
|
|
|
197,686 |
|
| Sales and marketing equipment and space modifications |
|
|
230,543 |
|
|
|
225,173 |
|
| Research and development equipment, software and space modifications |
|
|
1,444,531 |
|
|
|
1,213,195 |
|
| Research and development equipment, software and space modifications not in service |
|
|
- |
|
|
|
19,595 |
|
| Less accumulated depreciation |
|
|
(3,745,873) |
|
|
|
(3,538,455 |
) |
| Total property and equipment, net |
|
|
2,309,601 |
|
|
|
2,299,908 |
|
| |
|
|
|
|
|
|
|
|
| OTHER ASSETS: |
|
|
|
|
|
|
|
|
| Patents, net |
|
|
65,324 |
|
|
|
71,039 |
|
| Deposits and other |
|
|
81,560 |
|
|
|
46,820 |
|
| Total other assets |
|
|
146,884 |
|
|
|
117,859 |
|
| Total assets |
|
$ |
7,002,628 |
|
|
$ |
6,686,568 |
|
| CURRENT LIABILITIES: |
|
|
|
|
|
|
|
|
| Accounts payable |
|
$ |
543,342 |
|
|
$ |
301,627 |
|
| Term loan payable, current portion |
|
|
56,123 |
|
|
|
54,850 |
|
| Term loan payable (Related party), current portion |
|
|
59,396 |
|
|
|
— |
|
| Subordinated debentures payable, current portion |
|
|
36,897 |
|
|
|
33,371 |
|
| Customer deposits |
|
|
2,689 |
|
|
|
25,694 |
|
| Accrued expenses |
|
|
344,565 |
|
|
|
321,112 |
|
| Deferred revenue, current portion |
|
|
60,959 |
|
|
|
53,716 |
|
| Product warranty reserve |
|
|
46,500 |
|
|
|
46,500 |
|
| Total current liabilities |
|
|
1,150,471 |
|
|
|
836,870 |
|
| |
|
|
|
|
|
|
|
|
| TERM LOAN PAYABLE, net of current portion and debt issuance costs |
|
|
1,016,171 |
|
|
|
1,058,426 |
|
| |
|
|
|
|
|
|
|
|
| TERM LOAN PAYABLE (Related Party), net of current portion and debt issuance costs |
|
|
440,604 |
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
| SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs |
|
|
653,219 |
|
|
|
681,343 |
|
| |
|
|
|
|
|
|
|
|
| DEFERRED REVENUE, net of current portion |
|
|
10,359 |
|
|
|
6,151 |
|
| Total liabilities |
|
|
3,270,824 |
|
|
|
2,582,790 |
|
| |
|
|
|
|
|
|
|
|
| COMMITMENTS AND CONTINGENCIES (Note 6) |
|
|
|
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
| STOCKHOLDERS’ EQUITY: |
|
|
|
|
|
|
|
|
| Common stock, no par value; 50,000,000 shares authorized, 2,752,616 shares outstanding |
|
|
5,934,314 |
|
|
|
5,934,314 |
|
| Accumulated deficit |
|
|
(2,202,510) |
|
|
|
(1,830,536 |
) |
| Total stockholders’ equity |
|
|
3,731,804 |
|
|
|
4,103,778 |
|
| Total liabilities and stockholders’ equity |
|
$ |
7,002,628 |
|
|
$ |
6,686,568 |
|
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Profit (Loss) (Unaudited)
| | |
| | |
| |
| | |
Three Months Ended September 30, | |
| REVENUES: | |
2026 | | |
2025 | |
| Product sales | |
$ | 2,512,530 | | |
$ | 2,241,331 | |
| Royalties | |
| 9,344 | | |
| 16,117 | |
| Rental income | |
| — | | |
| — | |
| Total | |
| 2,521,874 | | |
| 2,257,448 | |
| | |
| | | |
| | |
| COST OF SALES | |
| 1,431,792 | | |
| 1,350,755 | |
| | |
| | | |
| | |
| GROSS PROFIT | |
| 1,090,082 | | |
| 906,693 | |
| | |
| | | |
| | |
| OPERATING EXPENSES: | |
| | | |
| | |
| Research, development, and sustaining engineering | |
| 505,982 | | |
| 458,747 | |
| Sales and marketing | |
| 314,948 | | |
| 341,567 | |
| General and administrative | |
| 319,223 | | |
| 340,705 | |
| Total | |
| 1,140,153 | | |
| 1,141,019 | |
| | |
| | | |
| | |
| OPERATING (LOSS) | |
| (50,071 | ) | |
| (234,326 | ) |
| | |
| | | |
| | |
| OTHER INCOME (EXPENSE): | |
| | | |
| | |
| Interest income | |
| 8,734 | | |
| 7,840 | |
| Interest expense | |
| (43,594 | ) | |
| (36,953 | ) |
| Total | |
| (34,860 | ) | |
| (29,113 | ) |
| | |
| | | |
| | |
| | |
| | | |
| | |
| BENEFIT FROM FEDERAL AND STATE INCOME TAXES | |
| — | | |
| — | |
| | |
| | | |
| | |
| NET (LOSS) | |
$ | (84,931 | ) | |
$ | (263,439 | ) |
| | |
| | | |
| | |
| NET (LOSS) PER SHARE, BASIC | |
$ | (0.03 | ) | |
$ | (0.10 | ) |
| | |
| | | |
| | |
| NET (LOSS) PER SHARE, DILUTED | |
$ | (0.03 | ) | |
$ | (0.10 | ) |
| | |
| | | |
| | |
| WEIGHTED AVERAGE SHARES, BASIC | |
| 2,752,616 | | |
| 2,752,616 | |
| | |
| | | |
| | |
| WEIGHTED AVERAGE SHARES, DILUTED | |
| 2,752,616 | | |
| 2,752,616 | |
| | |
| | | |
| | |
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Profit (Loss) (Unaudited)
| | |
| | |
| |
| | |
Nine Months Ended September 30, | |
| REVENUES: | |
2026 | | |
2025 | |
| Product sales | |
$ | 7,236,986 | | |
$ | 6,695,638 | |
| Royalties | |
| 23,657 | | |
| 41,588 | |
| Rental income | |
| — | | |
| 16,632 | |
| Total | |
| 7,260,643 | | |
| 6,753,858 | |
| | |
| | | |
| | |
| COST OF SALES | |
| 4,090,961 | | |
| 4,014,000 | |
| | |
| | | |
| | |
| GROSS PROFIT | |
| 3,169,682 | | |
| 2,739,858 | |
| | |
| | | |
| | |
| OPERATING EXPENSES: | |
| | | |
| | |
| Research, development, and sustaining engineering | |
| 1,480,708 | | |
| 1,551,689 | |
| Sales and marketing | |
| 949,145 | | |
| 1,015,651 | |
| General and administrative | |
| 1,021,478 | | |
| 1,065,657 | |
| Total | |
| 3,451,331 | | |
| 3,632,997 | |
| | |
| | | |
| | |
| OPERATING (LOSS) | |
| (281,649 | ) | |
| (893,139 | ) |
| | |
| | | |
| | |
| OTHER INCOME (EXPENSE): | |
| | | |
| | |
| Interest income | |
| 24,121 | | |
| 31,128 | |
| Interest expense | |
| (114,446 | ) | |
| (87,753 | ) |
| Total | |
| (90,325 | ) | |
| (56,625 | ) |
| | |
| | | |
| | |
| | |
| | | |
| | |
| BENEFIT FROM FEDERAL AND STATE INCOME TAXES | |
| — | | |
| — | |
| | |
| | | |
| | |
| NET (LOSS) | |
$ | (371,974 | ) | |
$ | (949,764 | ) |
| | |
| | | |
| | |
| NET (LOSS) PER SHARE, BASIC | |
$ | (0.14 | ) | |
$ | (0.35 | ) |
| | |
| | | |
| | |
| NET (LOSS) PER SHARE, DILUTED | |
$ | (0.14 | ) | |
$ | (0.35 | ) |
| | |
| | | |
| | |
| WEIGHTED AVERAGE SHARES, BASIC | |
| 2,752,616 | | |
| 2,733,490 | |
| | |
| | | |
| | |
| WEIGHTED AVERAGE SHARES, DILUTED | |
| 2,752,616 | | |
| 2,733,490 | |
| | |
| | | |
| | |
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Changes in Stockholders’
Equity (Unaudited)
For the Three and Nine Months Ended September
30, 2026 and 2025
| | |
| | |
| | |
| | |
| |
| | |
2026 | |
| | |
Common Stock Shares | | |
Common Stock Amount | | |
Accumulated Deficit | | |
Total | |
| Beginning balance, December 31, 2025 | |
| 2,752,616 | | |
$ | 5,934,314 | | |
$ | (1,830,536 | ) | |
$ | 4,103,778 | |
| Net (loss) | |
| — | | |
| — | | |
| (152,713 | ) | |
| (152,713 | ) |
| Ending balance, March 31, 2026 | |
| 2,752,616 | | |
| 5,934,314 | | |
| (1,983,249 | ) | |
| 3,951,065 | |
| Net (loss) | |
| — | | |
| — | | |
| (134,330 | ) | |
| (134,330 | ) |
| Ending balance, June 30, 2026 | |
| 2,752,616 | | |
| 5,934,314 | | |
| (2,117,579 | ) | |
| 3,816,735 | |
| Net (loss) | |
| — | | |
| — | | |
| (84,931 | ) | |
| (84,931 | ) |
| Ending balance, September 30, 2026 | |
| 2,752,616 | | |
$ | 5,934,314 | | |
$ | (2,202,510 | ) | |
$ | 3,731,804 | |
| | |
| | |
| | |
| | |
| |
| | |
2025 | |
| | |
Common Stock Shares | | |
Common Stock Amount | | |
Accumulated Deficit | | |
Total | |
| Beginning balance, December 31, 2024 | |
| 2,664,116 | | |
$ | 5,586,014 | | |
$ | 639,863 | | |
$ | 6,225,877 | |
| Issuance of shares from option exercise | |
| 88,500 | | |
| 336,300 | | |
| — | | |
| 336,300 | |
| Warrants issued with subordinated debenture | |
| — | | |
| 12,000 | | |
| — | | |
| 12,000 | |
| Net (loss) | |
| — | | |
| — | | |
| (292,686 | ) | |
| (292,686 | ) |
| Ending balance, March 31, 2025 | |
| 2,752,616 | | |
| 5,934,314 | | |
| 347,177 | | |
| 6,281,491 | |
| Net (loss) | |
| — | | |
| — | | |
| (393,639 | ) | |
| (393,639 | ) |
| Ending balance, June 30, 2025 | |
| 2,752,616 | | |
| 5,934,314 | | |
| (46,462 | ) | |
| 5,887,852 | |
| Net (loss) | |
| — | | |
| — | | |
| (263,439 | ) | |
| (263,439 | ) |
| Ending balance, September 30, 2025 | |
| 2,752,616 | | |
$ | 5,934,314 | | |
$ | (309,901 | ) | |
$ | 5,624,413 | |
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Cash Flows (Unaudited)
| | |
| | |
| |
| | |
Nine months Ended September 30, | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |
2026 | | |
2025 | |
| Net
(loss) | |
$ | (371,974 | ) | |
$ | (949,764 | ) |
| Adjustments
to reconcile net (loss) to net cash (used in) operating activities- | |
| | | |
| | |
| Provision
for doubtful accounts, net change | |
| — | | |
| 1,500 | |
| Depreciation
and amortization | |
| 213,133 | | |
| 325,095 | |
| Amortization
of debt issuance costs | |
| 18,153 | | |
| 11,937 | |
| Changes
in operating assets and liabilities- | |
| | | |
| | |
| Accounts
receivable | |
| (13,062 | ) | |
| (133,415 | ) |
| Inventories | |
| (44,420 | ) | |
| 134,239 | |
| Federal
and state income taxes receivable | |
| 600 | | |
| 24,729 | |
| Prepaid
expenses and other | |
| (35,922 | ) | |
| (102,583 | ) |
| Deposits
and other | |
| (34,740 | ) | |
| (34,559 | ) |
| Accounts
payable | |
| 241,715 | | |
| 133,342 | |
| Customer
deposits | |
| (23,005 | ) | |
| (25,885 | ) |
| Accrued
expenses | |
| 23,453 | | |
| 34,753 | |
| Deferred
revenue | |
| 11,451 | | |
| 2,174 | |
| Net cash
(used in) operating activities | |
| (14,618 | ) | |
| (578,437 | ) |
| | |
| | | |
| | |
| CASH
FLOWS (USED IN) INVESTING ACTIVITIES: | |
| | | |
| | |
| Purchases
of sales and marketing equipment | |
| (5,370 | ) | |
| (39,510 | ) |
| Purchases
of research and development equipment, software and space modifications | |
| (211,741 | ) | |
| (310,646 | ) |
| Net cash
(used in) investing activities | |
| (217,111 | ) | |
| (350,156 | ) |
| | |
| | | |
| | |
| CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES: | |
| | | |
| | |
| Principal
payments made on term loan | |
| (42,592 | ) | |
| (41,356 | ) |
| Proceeds
from issuance of subordinated debenture | |
| — | | |
| 75,000 | |
| Proceeds
(related party) from issuance of term loan | |
| 500,000 | | |
| — | |
| Principal
payments made on subordinated debentures | |
| (41,141 | ) | |
| — | |
| Proceeds
from issuance of shares from option exercise | |
| | | |
| 336,300 | |
| Net
cash provided from financing activities | |
| 416,267 | | |
| 369,944 | |
| | |
| | | |
| | |
| NET
INCREASE (DECREASE) IN CASH | |
| 184,538 | | |
| (558,649 | ) |
| | |
| | | |
| | |
| CASH,
BEGINNING OF PERIOD | |
| 746,001 | | |
| 1,243,746 | |
| | |
| | | |
| | |
| CASH,
END OF PERIOD | |
$ | 930,539 | | |
$ | 685,097 | |
| | |
| | | |
| | |
| SUPPLEMENTAL
INFORMATION: | |
| | | |
| | |
| Cash
paid for interest | |
$ | 96,292 | | |
$ | 75,816 | |
| | |
| | | |
| | |
| | |
| | | |
| | |
| Income
tax refund received | |
$ | — | | |
$ | 24,729 | |
| | |
| | | |
| | |
| Non-cash
financing and investing activities: warrants issued with subordinated debenture | |
$ | — | | |
$ | 12,000 | |